Trial Profile
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; House dust mite allergy immunotherapy Laboratorios LETI
- Indications Acute asthma
- Focus Therapeutic Use
- Acronyms EarlyAna
- 20 Jul 2020 Status changed from recruiting to withdrawn prior to enrolment. According to ClinicalTrials.gov, this trial has been Withdrawn. Reason: The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.
- 24 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2019 to 1 Jul 2019.
- 30 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2018 to 1 May 2019.